ClinicalTrials.gg
Active, not recruitingNCT06094179Updated Oct 2, 2026

Evaluate the Safety, Tolerability of BAT6026

A Phase 1/2 interventional study of Monoclonal antibody BAT6026 and sodium chloride injection in Dermatitis, Atopic, sponsored by Bio-Thera Solutions. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Bio-Thera Solutions · Phase 1/2, Interventional, and Treatment

Updated Oct 2, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 207 studies in Dermatitis, Atopic with a site in China — 65 open to participants now, 83 under way, 29 of them phase 3. Dermatitis, Atopic · China.

Planned enrollment
166th of 191
33 · median 163
Started
2023
with 38 others
Phase 1/2
15 of 207
5 open now
Primary completion
2026-12
later than 34 of 82 live
Registered
88th of 207
by date

Among the 207 studies in Dermatitis, Atopic with a site in China, this one is the 166th largest by planned enrollment of the 191 interventional ones that give a count, is one of 39 that started in 2023, is one of 15 in phase 1/2, reaches primary completion later than 34 of the 82 other live ones, and was the 88th registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

65 of the 207 studies in Dermatitis, Atopic with a site in China are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 207 studies in Dermatitis, Atopic with a site in China, or all of them as a file.
02

Study summary

This is a Phase IB/IIA clinical study of BAT6026 in patients with AD. The subjects were adults with moderate to severe atopic dermatitis (AD) whose disease was not adequately controlled by prior topical medications or for which topical medications were not appropriate. The first phase was the phase IB study, which was double-blind controlled by placebo in the group and consisted of 3 dose groups. After completing the dose escalation study, the phase IIA study was entered. The Phase IIA study was a randomized, double-blind, controlled, multicentering clinical trial with different dose groups and placebo groups. The primary endpoint was to explore the efficacy and safety of BAT6026 in patients with eczema area and severity index (EASI) of at least 75% lower than the baseline at week 16 after 4 treatment cycles. To provide the optimal dose for the phase III regimen.

03

Conditions studied

  • Dermatitis, Atopic

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily sign written and comply with the requirements of the research protocol;
  2. age 18-75 years old, male and female;
  3. According to the Hanifin-Rajka criteria, the patient was diagnosed with AD and had a history of at least 1 year;
  4. EASI score ≥16 during screening visit and baseline visit;
  5. IGA score ≥3 at screening and baseline (moderate);
  6. BSA involvement at screening and baseline was ≥10%;
  7. Received , phosphodiesterase inhibitors, or calcineurin inhibition in the 6 months prior to screening Drug, or phototherapy for AD and other local treatment options, and according to the judgment of the investigator, the local treatment response is insufficient (follow the doctor Local treatment is prescribed for at least 4 weeks or to the maximum recommended course of treatment in the product's prescribing information, whichever is shorter, which has not been achieved Is in remission or in a state of low disease activity (IGA 0 to 2), has no response or intolerance, or has a medical to the treatment, and is not suitable for the use of this local treatment;
  8. Steady-dose topical emollients (subjects must use investigator-recommended or investigator-approved base emollients that do not contain AD-affecting additives, such as hyaluronic acid, urea, ceramide, or filagmin) have been applied for at least 7 consecutive days prior to baseline visit and continued use during the study period; If the patient is screened before the visit has been started These moisturizers can then be used in steady doses;
  9. For women of childbearing age, it should not be during pregnancy or lactation; And all the subjects and their partners were in treatment

Exclusion criteria

Exclusion Criteria:

  1. Other inflammatory diseases that may confuse the diagnosis of AD or interfere with the evaluation of efficacy (e.g. Psoriasis, systemic erythematosus) Sore, scleroderma, mixed connective tissue disease, overlapping syndrome, etc.);
  2. any of the following laboratory test abnormalities existed before the first drug use (individual indicators during the screening period do not meet, rescreening qualified can still be accepted

    In) :

    1. \<100 g/L;
    2. White blood cell count (WBC) \<3.5×109/L;
    3. \<1.5×109/L;
    4. count \<100×109/L;
    5. (AST) or alanine aminotransferase (ALT) >2× (ULN);
    6. Total >1.5×ULN;
    7. Creatinine >1.2×ULN.
    8. abnormalities in other laboratory tests that, as determined by the investigator, may affect the completion or evaluation of the test;
  3. Have a history of alcohol or drug abuse, alcoholism or drug dependence within 1 year before screening; Poor compliance as assessed by the investigator (approved Inquire);
  4. Previous history of allergy to biological products or allergic to BAT6026 or any of its ;
  5. within 6 months before the first drug, did not receive standard treatment (SOC) or SOC failed to infected parasites;
  6. Systematic administration of antibiotics, antiviral drugs, antiparasitic drugs, antigenics or antigenics is required within 4 weeks before the first medication Antimicrobials are used to treat a variety of systemic infections, and the medical history assessed by the investigator or sponsor may interfere with subjects in this trial Safety, and efficacy evaluators;
  7. have severe liver, kidney, hematology, gastrointestinal, endocrine, lung, heart, central nervous system or sperm God disease;
  8. Patients with unstable or uncontrollable hypertension/diabetes need to be excluded, such as those who can be controlled and stabilized by drug treatment The researcher judged that it could continue to be included;
  9. Superficial skin infection exists within 2 weeks before the first medication;
  10. Received within 4 weeks before the first dose, except inactivated vaccine;
  11. Participated in any clinical trials 4 weeks before the first medication;
  12. Received systemic and other immunizations within 4 weeks or 5 half-lives (whichever is older) prior to the first dose Epidemic inhibitor therapy (e.g., cyclosporine, mycophenolate, interferon gamma, azathioprine, methotrexate, JAK enzyme suppression) Preparations), biological agents;
  13. Receive any of the following topical drugs for AD within 1 week before the first dose:

    Glucocorticoids (TCS); Calcineurin inhibitors or other ; JAK inhibitor; Antipruritic agents such as clomitone; Compound preparations containing corticosteroids or calcineurin inhibitors or other immunosuppressants; Prescription emollients that affect AD; Chinese herbal medicine, proprietary Chinese medicine and ethnic medicine for AD;

  14. Received natalizumab or other regulatory B or T cells within 12 months prior to the first dose Drug therapy, such as rituximab, alemtuzumab, abacil (abatacept), etc.
  15. Received whole-body phototherapy (narrow-spectrum ultraviolet B [NB-UVB], ultraviolet B [UVB], Ultraviolet A [UVA], psoralen combined with ultraviolet A [PUVA])
  16. Patients who had received major surgery within 4 weeks prior to the first dose or planned to undergo major surgery during the study period, or were unable to undergo surgery before randomization Complete recovery during operation;
  17. patients with a history of malignant tumors (completely cured cervical carcinoma in situ, non- skin squamous cell carcinoma, skin Other than basal cell carcinoma), or lymphoproliferative diseases;
  18. Patients who have received organ transplantation within 3 months before screening (corneal transplantation >3 months before the first administration of the experimental drug) External);
  19. Pregnant or lactating women, or women who wish to become pregnant;
  20. there are infected with the following diseases: active virus infection [Hepatitis B surface antigen (HBsAg) positive, and B Hepatovirus deoxyribonucleic acid (HBV-DNA) test >200 IU/ml or 103 copies /ml; Infected with virus [Positive results of HCV antibody and viral ribonucleic acid (HCV-RNA) detection]; Treponema pallidum antibody positive and RPR Positive or other confirmed tests;
  21. Active tuberculosis includes, but is not limited to, tuberculosis (TB) in patients who have been treated with standardized anti-TB therapy and have been confirmed cured by researchers Included) and patients with latent tuberculosis (positive for Tspot or Quantiferon); History of immunodeficiency, including human immunity A history of infection or other immunodeficiency diseases;
  22. Those who have participated in OX40 antibody research and used OX40 antibody before;
  23. Other conditions deemed unsuitable for study participation by the investigator.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
33 participants (estimated)

Study arms

  • Experimental
    A1 300mg

    Trial drug: Placebo 9:3 randomized double-blind admission. The last patient in each group was given the drug for 1 week, and the existing safety data was reviewed blind by SMC, and the next group was entered into the study after reaching the increasing standard

    Drug: Monoclonal antibody BAT6026 · Drug: sodium chloride injection

  • Experimental
    B1 600mg

    Trial drug: Placebo 9:3 randomized double-blind admission. The last patient in each group was given the drug for 1 week, and the existing safety data was reviewed blind by SMC, and the next group was entered into the study after reaching the increasing standard

    Drug: Monoclonal antibody BAT6026 · Drug: sodium chloride injection

  • Experimental
    C1 600mg

    Trial drug: Placebo 9:3 randomized double-blind admission. The last patient in each group was given the drug for 1 week, and the existing safety data was reviewed blind by SMC, and the next group was entered into the study after reaching the increasing standard

    Drug: Monoclonal antibody BAT6026 · Drug: sodium chloride injection

Interventions

  • 300mg Q4W group, 600mg Q4W group (at week 0,4,8,12) and 600mg Q2W group (at week 0,2,4,6,8,10,12,14)

    Also known as: BAT6026

  • 300mg Q4W group, 600mg Q4W group (at week 0,4,8,12) and 600mg Q2W group (at week 0,2,4,6,8,10,12,14)

06

What researchers measure

Primary outcomes

  1. tolerance

    Incidence of AE above 3 Arms associated with the test drug in each dose group

    Time frame: The last patient in each group was dosed 1 week later

  2. Vital signs

    Number of participants with abnormal vital signs

    Time frame: The last patient in each group was dosed 1 week later

  3. ECG parameters

    Number of participants with abnormal ECG readings

    Time frame: The last patient in each group was dosed 1 week later

  4. Laboratory tests

    Number of participants with abnormal laboratory test results

    Time frame: The last patient in each group was dosed 1 week later

  5. AEs, adverse events

    Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

    Time frame: The last patient in each group was dosed 1 week later

07

Study locations

1 site
  • Jianzhong Zhang
    Beijing, Beijing Municipality, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Dec 2026, 37 months after the start.

Of 25 industry-sponsored phase 1/2 interventional studies under Dermatitis, Atopic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 38. This study's planned 37 months is above that.

Counting every sponsor, half of 29 studies reached it within 22 months; a quarter within 8 and three quarters within 38.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Jun 2026 → Dec 2026 and completion Jun 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2023
First posted
Oct 23, 2023
StartActual
Nov 9, 2023
Primary completionEst.
Dec 31, 2026was Jun 2026
CompletionEst.
Dec 31, 2026was Jun 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 1, 2026→Dec 31, 2026
Oct 2, 2026
Study completion
Jun 30, 2026→Dec 31, 2026
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Primary completion Jun 1, 2026→Dec 31, 2026
    Study completion Jun 30, 2026→Dec 31, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06094179
Responsible party
Sponsor
First posted
Oct 23, 2023
Start date
Nov 9, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Oct 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vedastotug

Start the discussion